| Literature DB >> 32364962 |
Zhibing Luo1, Na Wang1, Ping Liu2, Qian Guo1, Linyu Ran1, Feilong Wang1, Yuling Tang3, Qiang Li4.
Abstract
PURPOSE: This retrospective study aims to illustrate the radiographic characteristics of Coronavirus Disease 2019 and the correlation with the clinical course.Entities:
Keywords: Computed tomography; Coronavirus disease; SARS-CoV2; Viral infection
Mesh:
Year: 2020 PMID: 32364962 PMCID: PMC7175878 DOI: 10.1016/j.rmed.2020.105989
Source DB: PubMed Journal: Respir Med ISSN: 0954-6111 Impact factor: 4.582
Radiographic characteristics of 195 patients diagnosed of COVID-19.
| Number (%) | |
|---|---|
| Age | 46 (33–59) |
| Sex | |
| Male | 94 (48.2%) |
| Female | 101 (51.8%)) |
| Non | 25 (12.8%) |
| Unilateral | 26 (13.3%) |
| Bilateral | 144 (73.8%) |
| 1 | 22 (11.3%) |
| 2 | 31 (15.9%) |
| 3 | 26 (13.3%) |
| 4 | 24 (12.3%) |
| 5 | 67 (34.4%) |
| Peripheral | 162 (83.1%) |
| Central | 8(4.1%) |
| GGO | 80 (41.0%) |
| Solitary GGN/GGO | 20 (10.3%) |
| Patchy ground-glass opacities | 100 (51.3%) |
| Consolidation | 89 (45.6%) |
| Increased vascular margins | 123 (63.1%) |
| Long Axis Parallelism | 109 (55.9%) |
| Nodule with halo sign | 87 (44.6%) |
| Parenchymal band | 84 (43.1%) |
| Reversed halo sign | 62 (31.8%) |
| Air bronchogram | 58 (29.7%) |
| Crazy paving | 11 (5.6%) |
| Pleural effusion | 6 (3.1%) |
| Mediastinal lymphadenopathy | 2 (1.0%) |
GGO, ground-glass opacification; GGN, ground-glass nodule.
Fig. 1Chest CT scan features of COVID-19. a-b. GGO. c. GGN. d. Crazy Paving Pattern. e. Long Axis Parallelism. f. Patchy Ground-glass Opacities. g. Increased Vascular Margins. h. Consolidation. i. Nodule with Halo Sign. j. Air Bronchogram. k. Reversed Halo Sign. l. Parenchymal Bands.
Radiographic evolution of COVID-19 along with time course.
| No. (%) | P value | ||||
|---|---|---|---|---|---|
| Duration | Super Early | Early | Intermediate | Late | |
| Age | 50.6 ± 25.5 | 47.9 ± 18.3 | 43.5 ± 15.2 | 45.3 ± 14.2 | 0.345 |
| Sex | |||||
| Male | 7 (58.3%) | 24 (45.3%) | 36 (44.4%) | 27 (55.1%) | 0.577 |
| Female | 5 (41.7%) | 29 (54.7%) | 45 (55.6%) | 22 (44.9%) | |
| Non | 3 (25.0%) | 6 (11.3%) | 11 (13.6%) | 5 (10.2%) | 0.596 |
| Unilateral | 4 (33.3%) | 11 (20.8%) | 4 (4.9%) | 7 (14.3%) | 0.009 |
| Bilateral | 5 (41.7%) | 36 (67.9%) | 66 (81.5%) | 37 (75.5%) | 0.018 |
| 1 | 4 (33.3%) | 9 (17.0%) | 3 (3.7%) | 6 (12.2%) | 0.007 |
| 2 | 1 (8.3%) | 9 (17.0%) | 13 (16.0%) | 8 (16.3%) | 0.904 |
| 3 | 3 (25.0%) | 6 (11.3%) | 12 (14.8%) | 5 (10.2%) | 0.538 |
| 4 | 0 (0.0%) | 8 (15.1%) | 10 (12.3%) | 6 (12.2%) | 0.559 |
| 5 | 1 (8.3%) | 15 (28.3%) | 32 (39.5%) | 19 (38.8%) | 0.120 |
| Peripheral | 6 (50.0%) | 44 (83.0%) | 69 (85.2%) | 43 (87.8%) | 0.016 |
| Central | 3 (25.0%) | 3 (5.7%) | 1 (1.2%) | 1 (2.0%) | 0.007 |
| GGO | 5 (41.7%) | 24 (45.3%) | 22 (27.2%) | 29 (59.2%) | 0.004 |
| Solitary GGN/GGO | 4 (33.3%) | 7 (13.2%) | 5 (6.2%) | 4 (8.2%) | 0.027 |
| Increased Vascular Margins | 6 (50.0%) | 35 (66.0%) | 51 (63.0%) | 31 (63.3%) | 0.781 |
| Nodule with Halo Sign | 5 (41.7%) | 22 (41.5%) | 44 (54.3%) | 16 (32.7%) | 0.103 |
| Consolidation | 4 (33.3%) | 24 (45.3%) | 47 (58.0%) | 14 (28.6%) | 0.009 |
| Air Bronchogram | 2 (16.7%) | 17 (32.1%) | 27 (33.3%) | 12 (24.5%) | 0.519 |
| Reversed Halo Sign | 1 (8.3%) | 14 (26.4%) | 34 (42.0%) | 13 (26.5%) | 0.041 |
| Patchy Ground-glass Opacities | 2 (16.7%) | 29 (54.7%) | 45 (55.6%) | 24 (49.0%) | 0.082 |
| Parenchymal Band | 2 (16.7%) | 18 (34.0%) | 38 (46.9%) | 26 (53.1%) | 0.053 |
| Long Axis Parallelism | 4 (33.3%) | 20 (37.7%) | 52 (64.2%) | 33 (67.3%) | 0.002 |
| Crazy Paving | 1 (8.3%) | 3 (5.7%) | 4 (4.9%) | 3 (6.1%) | 0.870 |
| Mediastinal LAD | 0 (0.0%) | 2 (3.8%) | 0 (0.0%) | 0 (0.0%) | 0.255 |
| Pleural Effusion | 0 (0.0%) | 1 (1.9%) | 4 (4.9%) | 1 (2.0%) | 0.769 |
GGO, ground-glass opacification; GGN, ground-glass nodule; LAD, lymphadenopathy.
COVID-19 progression assessments and correlation with radiographic features.
| Number | P value | ||
|---|---|---|---|
| Outcome | Improving or Stable | Worsening | |
| Number | 80 | 15 | |
| Age | 45.3 ± 15.0 | 59.3 ± 13.5 | |
| Sex | |||
| Male | 37 (46.3%) | 6 (40.0%) | 0.655 |
| Female | 43 (53.8%) | 9 (60.0%) | |
| Non | 7 (8.8%) | 0 (0.0%) | 0.514 |
| Unilateral | 9 (11.3%) | 0 (0.0%) | 0.376 |
| Bilateral | 64 (80.0%) | 15 (100%) | 0.128 |
| 1 | 7 (8.8%) | 0 (0.0%) | 0.514 |
| 2 | 11 (13.8%) | 2 (13.3%) | 1.000 |
| 3 | 14 (17.5%) | 2 (13.3%) | 0.984 |
| 4 | 11 (13.8%) | 4 (26.7%) | 0.247 |
| 5 | 30 (37.5%) | 7 (46.7%) | 0.504 |
| Peripheral | 70 (87.5%) | 14 (93.3%) | 0.835 |
| Central | 3 (3.8%) | 1 (6.7%) | 0.503 |
| GGO | 34 (42.5%) | 7 (46.7%) | 0.765 |
| Solitary GGN/GGO | 8 (10.0%) | 0 (0.0%) | 0.439 |
| Patchy Ground-glass Opacities | 42 (52.5%) | 9 (60.0%) | 0.593 |
| Consolidation | 39 (48.8%) | 8 (53.3%) | 0.745 |
| Increased Vascular Margins | 45 (56.3%) | 9 (60.0%) | 0.788 |
| Long Axis Parallelism | 50 (62.5%) | 8 (53.3%) | 0.504 |
| Nodule with Halo Sign | 38 (47.5%) | 5 (33.3%) | 0.312 |
| Parenchymal Band | 39 (48.8%) | 7 (46.7%) | 0.882 |
| Reversed Halo Sign | 28 (35.0%) | 5 (33.3%) | 0.901 |
| Air Bronchogram | 23 (28.7%) | 7 (46.7%) | 0.286 |
| Crazy Paving | 5 (6.3%) | 3 (20.0%) | 0.210 |
| Pleural Effusion | 2 (2.5%) | 0 (0.0%) | 1.000 |
| Mediastinal LAD | 1 (1.3%) | 0 (0.0%) | 1.000 |
GGO, ground-glass opacification; GGN, ground-glass nodule; LAD, lymphadenopathy.
Fig. 2Radiographic comparison between the first and second CT scan 3 days later. 2a-b. Decreased area and density of GGO. 2c-d. Increased area and density of GGO.
Correlation between laboratory test results and CT scan findings.
| Characteristic | All Patients | Positive CT | Negative CT | P value |
|---|---|---|---|---|
| 187 | 164 | 23 | ||
| Age | 43.0 (32.0–58.0) | 46.0 (35.0–60.0) | 31.0 (12.0–37.0) | |
| Fever (°C) | ||||
| ˃39.0 | 13 (7.0%) | 12 (7.3%) | 1 (4.3%) | |
| 38.1 to 39.0 | 62 (33.2%) | 60 (36.6%) | 2 (8.7%) | |
| 37.3 to 38.0 | 63 (33.7%) | 53 (32.3%) | 10 (43.5%) | |
| <37.3 | 49 (26.2%) | 39 (23.8%) | 10 (43.5%) | |
| + | – | |||
| WBC (*10^9/L) | 4.69 (3.62–5.78) | 4.62 (3.59–5.66) | 6.06 (4.15–7.73) | |
| Neutrophil % | 63.2 (55.3–71.9) | 64.8 (56.7–73.0) | 53.3 (46.1–60.7) | |
| Lymphocyte % | 27.3 (19.9–35.2) | 25.9 (18.5–32.7) | 38.6 (29.2–43.7) | |
| Albumin (g/L) | 37.66 (35.19–40.38) | 36.91 (34.38–39.84) | 42.01 (39.17–43.35) | |
| LDH (U/L) | 168.4 (141.1–215.5) | 174.0 (142.8–224.4) | 145.4 (110.2–164.4) | |
| CRP (mg/L) | 15.69 (4.93–29.85) | 18.60 (8.30–31.61) | 2.88 (2.36–5.30) | |
| ESR (mm/h) | 40.0 (22.0–67.3) | 50.0 (25.5–72.5) | 22.0 (10.5–27.5) | |
WBC, white blood cell; LDH, lactate dehydrogenase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.